Dr. Tamer El-Hossieny, Vice Chairman of the Egyptian Drug Authority (EDA), on behalf of Dr. Ali Al-Ghamrawy, Chairman of the EDA, held an extensive meeting with representatives of pharmaceutical import companies to discuss the latest updates on the implementation of the pharmaceutical track and trace system and its application mechanisms within companies. The meeting was held as part of the Authority’s commitment to ensuring the highest standards of quality, control, and safety in the circulation of pharmaceutical products in the Egyptian market.
Dr. El- Hossieny emphasized that the pharmaceutical track and trace system is one of the EDA’s most important strategic initiatives, as it enhances transparency and oversight of the movement of pharmaceutical products within the market, ensuring the highest levels of quality and patient safety.
He pointed out that the Authority does not only issue regulatory frameworks but also continuously monitors field implementation and provides technical and operational support to companies to facilitate application and address any challenges that may arise during the operational phases.
The Vice Chairman stressed that continuous collaboration between the EDA and stakeholders in the pharmaceutical sector is a key pillar in achieving the system’s objectives and ensuring national pharmaceutical products security, emphasizing the Authority’s commitment to continuing dialogue and discussing the technical and regulatory aspects necessary to enhance performance and improve operational efficiency.
He further explained that the implementation of the track and trace system is based on a participatory approach between the Authority and all relevant stakeholders, noting that this cooperation is essential to achieve a safer and more transparent pharmaceutical environment.
For their part, Representatives of the import companies praised the effective role of the Egyptian Drug Authority in organizing and developing the pharmaceutical sector, appreciating its efforts in supporting companies and providing the necessary technical guidance for efficient implementation of the system.
They emphasized that the Authority has become a model of transparency and alignment with global standards, adding that continuous collaboration between the EDA and the private sector contributes to improving product quality and safeguarding citizens' health.
Attending the meeting from the EDA were Counselor Sherif Magdy, Vice President of the State Council and Legal Advisor to the Chairman of the EDA; Dr. Amira Mahgoub, Head of the Central Administration for Inspection of Pharmaceutical Establishments; and Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access.
From the import companies, several senior leaders and representatives of global firms participated, including Pfizer, Novartis, Boehringer, Servier, Roche, MSD, Astellas, AbbVie, Novo Nordisk, GlaxoSmithKline, Merck, AstraZeneca, Abbott, Sandoz, Opella Healthcare, and Bayer, in addition to representatives from DAF Digital Solutions.